Anti-EGF 抗体 (ab9695)
Key features and details
- Rabbit polyclonal to EGF
- Suitable for: WB, IHC-P, ELISA, Neutralising, Sandwich ELISA
- Reacts with: Human, Recombinant fragment
- Isotype: IgG
リコンビナント抗体で、ロット間での高い再現性を実現
- 異なるロット間での安定した再現性
- 容易なスケールアップ
- 評価試験による特異性の確認済み
- 倫理基準に準拠 - アニマル・フリーの生産
製品の概要
-
製品名
Anti-EGF antibody
EGF 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to EGF -
由来種
Rabbit -
アプリケーション
適用あり: WB, IHC-P, ELISA, Neutralising, Sandwich ELISAmore details -
種交差性
交差種: Human, Recombinant fragment -
免疫原
Recombinant full length protein corresponding to Human EGF. Highly pure (>98%) recombinant hEGF (human Epidermal Growth Factor)
Database link: P01133 -
特記事項
Although some customers have been successful in IHC we no longer batch test in this application. For IHC validate antibody please see ab184265.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Lyophilized:Reconstitute with 200µl of sterile water. -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
バッファー
No preservative, sterile filtered -
Concentration information loading...
-
精製度
Immunogen affinity purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
軽鎖の種類
unknown -
研究分野
関連製品
-
Positive Controls
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab9695の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB | (2) |
Use a concentration of 0.1 - 0.2 µg/ml. To detect hEGF by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hEGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Western blot bands should be around 6.2 kDa.
|
IHC-P | (1) |
Use at an assay dependent concentration.
|
ELISA |
Use at an assay dependent concentration.
To detect hEGF by direct ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hEGF. |
|
Neutralising |
Use at an assay dependent concentration.
To yield one-half maximal inhibition [ND50] of the biological activity of hEGF (2.0 ng/ml), a concentration of 0.25 - 0.35 µg/ml of this antibody is required. |
|
Sandwich ELISA |
Use a concentration of 0.5 - 2 µg/ml.
For sandwich ELISA, use this antibody as Detection at 0.5µg/ml with ab18635 as Capture. |
特記事項 |
---|
WB
Use a concentration of 0.1 - 0.2 µg/ml. To detect hEGF by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hEGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Western blot bands should be around 6.2 kDa. |
IHC-P
Use at an assay dependent concentration. |
ELISA
Use at an assay dependent concentration. To detect hEGF by direct ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hEGF. |
Neutralising
Use at an assay dependent concentration. To yield one-half maximal inhibition [ND50] of the biological activity of hEGF (2.0 ng/ml), a concentration of 0.25 - 0.35 µg/ml of this antibody is required. |
Sandwich ELISA
Use a concentration of 0.5 - 2 µg/ml. For sandwich ELISA, use this antibody as Detection at 0.5µg/ml with ab18635 as Capture. |
ターゲット情報
-
機能
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro (PubMed:10964941). -
組織特異性
Expressed in kidney, salivary gland, cerebrum and prostate. -
関連疾患
Hypomagnesemia 4 -
配列類似性
Contains 9 EGF-like domains.
Contains 9 LDL-receptor class B repeats. -
翻訳後修飾
O-glycosylated with core 1-like and core 2-like glycans. It is uncertain if Ser-954 or Thr-955 is O-glycosylated. The modification here shows glycan heterogeneity: HexHexNAc (major) and Hex2HexNAc2 (minor). -
細胞内局在
Membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 1950 Human
- Omim: 131530 Human
- SwissProt: P01133 Human
- Unigene: 419815 Human
-
別名
- Beta urogastrone antibody
- beta-urogastrone antibody
- EGF antibody
see all
画像
-
Primary ab9695 was used at a dilution of 0.2 ug/ml.
Lane 1: 250 ng Recombinant human EGF protein
Lane 2: 125 ng Recombinant human EGF protein
データシートおよび資料
-
Datasheet download
参考文献 (34)
ab9695 は 34 報の論文で使用されています。
- Gao J et al. p130Cas is required for androgen-dependent postnatal development regulation of submandibular glands. Sci Rep 13:5144 (2023). PubMed: 36991029
- Durgun C et al. Investigation of the histopathological level of Ki-67, caspase-3 expressions of the effects of hesperidin on wound healing in the rat esophagus. Acta Cir Bras 38:e381723 (2023). PubMed: 37098927
- Vazana-Netzarim R et al. Distinct HAND2/HAND2-AS1 Expression Levels May Fine-Tune Mesenchymal and Epithelial Cell Plasticity of Human Mesenchymal Stem Cells. Int J Mol Sci 24:N/A (2023). PubMed: 38003736
- Valente WAS et al. Expression of epithelial growth factors and of apoptosis-regulating proteins, and presence of CD57+ cells in the development of inflammatory periapical lesions. J Appl Oral Sci 30:e20210413 (2022). PubMed: 35195153
- Park JY et al. The Potential of Transforming Growth Factor-beta Inhibitor and Vascular Endothelial Growth Factor Inhibitor as Therapeutic Agents for Uterine Leiomyoma. Int J Med Sci 19:1779-1786 (2022). PubMed: 36313223